As a participant in all three editions of the supply chain expo, Novo Nordisk is joining more industrial chain partners this year to build a comprehensive health management ecosystem that drives ...

Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Hims & Hers Health, Inc. (NYSE: HIMS) and certain of the Company's senior executives for ...

Some health experts view GLP-1s as a promising option for PCOS, which lacks a standard treatment and affects millions of ...

Novo Nordisk sees solid Q1 results, major GLP-1 growth potential, and limited downside despite guidance cut and rising risks.

With global demand for GLP-1-based drugs rising, Indian CDMOs are ramping up peptide capabilities ahead of key patent ...

The Canadian researcher has just received the Frontiers of Knowledge Award for his work on anti-obesity drugs. However, he ...

In a report released on July 17, David Evans from Kepler Capital maintained a Buy rating on Novartis AG, with a price target of CHF106.00. The company’s shares closed yesterday at CHF92.29. Evans ...